Barclays PLC Has $131.21 Million Holdings in Cencora, Inc. $COR

Barclays PLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 2.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 388,469 shares of the company’s stock after buying an additional 10,248 shares during the quarter. Barclays PLC’s holdings in Cencora were worth $131,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the stock. Vestcor Inc raised its stake in Cencora by 0.5% during the 3rd quarter. Vestcor Inc now owns 5,196 shares of the company’s stock valued at $1,624,000 after purchasing an additional 28 shares during the last quarter. JFS Wealth Advisors LLC raised its stake in Cencora by 30.2% during the 4th quarter. JFS Wealth Advisors LLC now owns 125 shares of the company’s stock valued at $42,000 after purchasing an additional 29 shares during the last quarter. Apollon Wealth Management LLC increased its holdings in Cencora by 0.5% in the 4th quarter. Apollon Wealth Management LLC now owns 6,527 shares of the company’s stock valued at $2,205,000 after buying an additional 30 shares during the period. Accent Capital Management LLC increased its holdings in Cencora by 36.1% in the 4th quarter. Accent Capital Management LLC now owns 113 shares of the company’s stock valued at $38,000 after buying an additional 30 shares during the period. Finally, MCF Advisors LLC increased its holdings in Cencora by 11.0% in the 4th quarter. MCF Advisors LLC now owns 303 shares of the company’s stock valued at $102,000 after buying an additional 30 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Down 0.0%

COR opened at $281.58 on Tuesday. The firm’s 50-day simple moving average is $288.36 and its 200-day simple moving average is $326.67. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54. The firm has a market cap of $54.78 billion, a price-to-earnings ratio of 21.59, a PEG ratio of 1.52 and a beta of 0.59.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period in the previous year, the company posted $4.42 EPS. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora announced that its board has authorized a stock buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio is presently 18.40%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on COR shares. Robert W. Baird lowered their price target on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. William Blair started coverage on shares of Cencora in a report on Tuesday, April 28th. They issued a “market perform” rating on the stock. Wells Fargo & Company lowered their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Finally, Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Twelve research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $374.00.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.